• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia.蒽环类药物剂量强化可改善接受核心结合因子急性髓系白血病治疗患者的分子反应及预后。
Haematologica. 2014 Oct;99(10):e185-7. doi: 10.3324/haematol.2014.109827. Epub 2014 Jun 27.
2
Long-term survival after significant treatment reduction in a patient with CBF-AML.一名CBF-AML患者在大幅减少治疗后长期存活。
Pediatr Blood Cancer. 2011 Feb;56(2):325-6. doi: 10.1002/pbc.22854. Epub 2010 Nov 11.
3
Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).尝试优化无核心结合因子的儿童急性髓细胞白血病的诱导后治疗：来自日本儿科白血病/淋巴瘤研究组（JPLSG）的报告。
Pediatr Blood Cancer. 2020 Dec;67(12):e28692. doi: 10.1002/pbc.28692. Epub 2020 Sep 4.
4
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?核心结合因子急性髓系白血病（CBF-AML）：大剂量阿糖胞苷（HDAC）巩固治疗是否如你所想的那样有效？
Curr Opin Hematol. 2009 Mar;16(2):92-7. doi: 10.1097/MOH.0b013e3283257b18.
5
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.核心结合因子急性髓系白血病的治疗：为获得更好的长期结果而不断改进。
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):153-8. doi: 10.1016/j.clml.2012.11.006. Epub 2012 Dec 21.
6
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).二次诱导化疗采用大剂量阿糖胞苷和米托蒽醌：对伴有 t(8;21)和 inv(16)的儿童急性髓系白血病患者的不同影响。
Blood. 2011 Nov 17;118(20):5409-15. doi: 10.1182/blood-2011-07-364661. Epub 2011 Sep 26.
7
Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.miRNA 结合位点多态性与阿糖胞苷和蒽环类药物代谢途径基因与急性髓系白血病患者的结局相关。
J Transl Med. 2017 Nov 15;15(1):235. doi: 10.1186/s12967-017-1339-9.
8
What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?治疗急性髓系白血病诱导缓解时，柔红霉素的最佳剂量和给药方案是什么？
Curr Treat Options Oncol. 2017 Jan;18(1):3. doi: 10.1007/s11864-017-0446-4.
9
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.核心结合因子急性髓系白血病：异质性、监测和治疗。
Am J Hematol. 2014 Dec;89(12):1121-31. doi: 10.1002/ajh.23821. Epub 2014 Aug 27.
10
Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.不同剂量阿糖胞苷诱导核心结合因子急性髓系白血病的临床异质性。
Sci Rep. 2020 Jan 20;10(1):685. doi: 10.1038/s41598-020-57414-y.

引用本文的文献

1
Paradigm Shift in the Management of Acute Myeloid Leukemia-Approved Options in 2023.2023年急性髓系白血病管理的范式转变——获批的治疗选择
Cancers (Basel). 2023 May 31;15(11):3002. doi: 10.3390/cancers15113002.
2
Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia.白三烯促进急性髓系白血病中干细胞自我更新和化疗耐药性。
Leukemia. 2022 Jun;36(6):1575-1584. doi: 10.1038/s41375-022-01579-0. Epub 2022 Apr 23.
3
[Chinese consensus on minimal residual disease detection and interpretation of patients with acute myeloid leukemia (2021)].《急性髓系白血病患者微小残留病检测与解读中国专家共识（2021年版）》
Zhonghua Xue Ye Xue Za Zhi. 2021 Nov 14;42(11):889-897. doi: 10.3760/cma.j.issn.0253-2727.2021.11.002.
4
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.2021 年急性髓系白血病微小残留病更新：来自欧洲白血病网微小残留病工作组的共识文件。
Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626.
5
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.可测量残留病作为急性髓细胞白血病的生物标志物：理论与实际考虑。
Leukemia. 2021 Jun;35(6):1529-1538. doi: 10.1038/s41375-021-01230-4. Epub 2021 Mar 23.
6
MRD Tailored Therapy in AML: What We Have Learned So Far.急性髓系白血病中微小残留病定制疗法：我们目前所了解的情况。
Front Oncol. 2021 Jan 15;10:603636. doi: 10.3389/fonc.2020.603636. eCollection 2020.
7
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.达沙替尼联合化疗用于初治核心结合因子急性髓系白血病：癌症和白血病B组研究10801
Blood Adv. 2020 Feb 25;4(4):696-705. doi: 10.1182/bloodadvances.2019000492.
8
Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies.急性髓系白血病患儿微小残留病的流式细胞术监测：最新进展与未来策略
Front Pediatr. 2019 Oct 11;7:412. doi: 10.3389/fped.2019.00412. eCollection 2019.
9
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.异基因造血细胞移植可改善 t(6;9) 急性髓系白血病成人患者的预后：一项国际协作研究的结果。
Haematologica. 2020 Jan;105(1):161-169. doi: 10.3324/haematol.2018.208678. Epub 2019 Apr 19.
10
Clinical implications of molecular markers in acute myeloid leukemia.急性髓细胞白血病中分子标志物的临床意义。
Eur J Haematol. 2019 Jan;102(1):20-35. doi: 10.1111/ejh.13172. Epub 2018 Oct 23.

本文引用的文献

1
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.MRD 导向的危险分层治疗可能改善首次完全缓解时 t(8;21) AML 的结局：来自 AML05 多中心试验的结果。
Blood. 2013 May 16;121(20):4056-62. doi: 10.1182/blood-2012-11-468348. Epub 2013 Mar 27.
2
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.核心结合因子急性髓系白血病患者基因突变和微小残留病的前瞻性评估。
Blood. 2013 Mar 21;121(12):2213-23. doi: 10.1182/blood-2012-10-462879. Epub 2013 Jan 15.
3
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.定量 RT-PCR 检测核心结合因子 AML 中的微小残留病可进行风险分层并预测复发：英国 MRC AML-15 试验的结果。
Blood. 2012 Oct 4;120(14):2826-35. doi: 10.1182/blood-2012-06-435669. Epub 2012 Aug 8.
4
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.吉妥珠单抗奥佐米星治疗初治成人急性髓系白血病的疗效（ALFA-0701）：一项随机、开放标签、3 期研究。
Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5.
5
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.鉴定能够从吉妥珠单抗奥佐米星治疗中获益的急性髓细胞性白血病患者：MRC AML15 试验的结果。
J Clin Oncol. 2011 Feb 1;29(4):369-77. doi: 10.1200/JCO.2010.31.4310. Epub 2010 Dec 20.
6
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.低危和中危细胞遗传学急性髓细胞白血病（AML）患者在首次复发时使用吉妥珠单抗和阿糖胞苷与阿糖胞苷相比的结果：一项回顾性比较研究的结果。
Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18.
7
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.成人急性髓系白血病的诊断和治疗：代表欧洲白血病网的国际专家小组的建议。
Blood. 2010 Jan 21;115(3):453-74. doi: 10.1182/blood-2009-07-235358. Epub 2009 Oct 30.
8
Anthracycline dose intensification in acute myeloid leukemia.急性髓系白血病中蒽环类药物剂量强化
N Engl J Med. 2009 Sep 24;361(13):1249-59. doi: 10.1056/NEJMoa0904544.
9
High-dose daunorubicin in older patients with acute myeloid leukemia.老年急性髓系白血病患者使用大剂量柔红霉素治疗
N Engl J Med. 2009 Sep 24;361(13):1235-48. doi: 10.1056/NEJMoa0901409.
10
Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.常规化疗治疗的老年急性髓系白血病伴（8；21）易位或（16）倒位：法国CBF-AML协作组的一项合作研究
J Clin Oncol. 2009 Oct 1;27(28):4747-53. doi: 10.1200/JCO.2008.21.0674. Epub 2009 Aug 31.

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia.

作者信息

Prebet Thomas, Bertoli Sarah, Delaunay Jacques, Pigneux Arnaud, Delabesse Eric, Mozziconacci Marie Joelle, Bidet Audrey, Recher Christian, Vey Norbert

机构信息

Hematology Department, Institut Paoli Calmettes, Marseille

Hematology Department, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse cedex 9.

出版信息

Haematologica. 2014 Oct;99(10):e185-7. doi: 10.3324/haematol.2014.109827. Epub 2014 Jun 27.

DOI:10.3324/haematol.2014.109827
PMID:24972769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4181266/
Abstract
摘要